Alliance for Lupus Research (ALR) and Pfizer’s Centers for Therapeutic Innovation (CTI) are partnering to discover new therapies for patients living with lupus. As part of this first-of-its-kind collaboration in lupus, ALR and CTI will co-fund novel translational research projects driven by leading academic medical centers within the CTI network.
The partnership is designed to enable joint project teams, consisting of Pfizer scientists and academic researchers, to translate novel scientific ideas into therapeutics that address unmet medical need. “Bringing new treatment options to people with lupus is our priority at ALR. We are thrilled to be working with CTI. The potential to quickly move promising therapeutics from the lab into Phase I clinical trials is something we are all very excited about,” said Ken Farber, president, ALR.
The CTI and ALR collaboration represents an evolution of the R&D ecosystem that CTI is designed to achieve, in which industry works in close partnership with academia, non-profit organizations, and other stakeholders to advance research and benefit patients. “It is clear that ALR shares CTI’s entrepreneurial spirit and quest for innovation, and we are excited to be partnering with ALR to find new treatment options for lupus," said Anthony J. Coyle, vice president & chief scientific officer, CTI.
This new collaboration maintains the key partnership attributes and principles that CTI has established with its network of leading academic medical centers. The parties anticipate that research projects may be commenced in the first half of 2013.
Date: November 7, 2012
Source: Alliance for Lupus Research